Tarsus Pharmaceuticals completes acquisition of Alkeus Pharmaceuticals - TARS News | RalliesTarsus Pharmaceuticals completes acquisition of Alkeus Pharmaceuticals
T
TARS• Tarsus closes Alkeus acquisition
- Tarsus completed its acquisition of Alkeus, adding worldwide rights to ALK-001, a late-stage oral candidate for Stargardt disease.
- ALK-001 is being evaluated in the global NORTHSTAR Phase 3 trial, with topline data expected in 2029.
- The program carries FDA Breakthrough Therapy, Orphan Drug, Fast Track, and Rare Pediatric Disease designations for Stargardt disease.
- The deal was announced on Aug. 6, 2026, then closed following satisfaction of customary closing conditions under the merger agreement.
